
How patients feel during treatment for cancer can have a lot to do with outcomes-and with the cost of care.
How patients feel during treatment for cancer can have a lot to do with outcomes-and with the cost of care.
Ethan Basch, MD, a self-described triple-threat, discusses incorporating patient-centered outcomes into clinical trials. He begins his presentation by describing a colleague's published research article, Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. The study found that not only did Pazopanib cost an estimated $5800 and Sunitinib $7800, but Pazopanib was superior to Sunitiniib in 11 out of 14 quality-of-life indicators.
Published: December 28th 2013 | Updated:
Published: January 29th 2014 | Updated:
259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831
© 2025 MJH Life Sciences®
All rights reserved.